Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525590 · ClinicalTrials.gov registry record · Phase 2
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT00525590 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 69 participants.
The verdict
NCT00525590, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of the surgical intervention and insertion of GLIADEL wafers on the neurocognitive functioning in patients with metastatic brain cancer.
Interventions
- DRUG GLIADEL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2007-12-12 |
| Est. Completion | 2010-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525590
The ClinicalTrials.gov registry entry for NCT00525590 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GLIADEL is the first listed.
NCT00525590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00525590 about?
NCT00525590 is a clinical study titled "Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer". The purpose of this study is to determine the effect of the surgical intervention and insertion of GLIADEL wafers on the neurocognitive functioning in patients with metastatic brain cancer.
What is the current status of trial NCT00525590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2007-12-12. Estimated completion is 2010-12-01.
What interventions are being tested in trial NCT00525590?
The interventions under investigation include: GLIADEL (DRUG).
Who is sponsoring clinical trial NCT00525590?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.